MDGL
MADRIGAL PHARMACEUTICALS, INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- May 6 ▲ Madrigal Pharmaceuticals reported Q1 2026 Rezdiffra net sales of $31…
- Jun 30 ▲ 3 funds open new positions (13F)
- Jul 20 ▼ 1 insider sell $1.4M at $547.30
- Jul 30 ▲ Madrigal Pharmaceuticals reported Q2 2026 Rezdiffra net sales of $36…
- Aug 17 ▼ 1 insider sell $341.9K at $514.97
- Sep 9 to Sep 11 ▼ 2 days of insider sells: $6.2M by 1 insider, avg $538.65
- Sep 23 Citigroup initiates
- Nov 3 ▲ Madrigal Pharmaceuticals reported Q3 2026 revenue of $431.3M (50% Yo…
- Nov 3 ▲ Madrigal Pharmaceuticals reported Q3 2026 Rezdiffra net sales of $43…
- Nov 4 to Nov 6 ▲ 2 days of insider buys: $35.0M by 1 insider, avg $381.49
- Nov 5 FDA: Madrigal Announces New Real-World Data at AASLD 2026 Demon…
- Nov 6 ▼ 1 insider sell $430.8K at $400.00
Signal stack
Where each data set points today.
- InsidersBULLISH
1 insider bought $35.0M at an average $381.49. 2 insiders sold $8.4M. Price is 11% above their cost.
- InstitutionsMIXED
Q2 2026: 36 added (3 new), 32 trimmed or exited. Largest new: Holocene Advisors $82.1M, Hrt Financial $45.4M.
- AnalystsBULLISH
24 of 26 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest −2.6% to 2.14M shares. 7.6 days to cover, ≈9.2% of shares.
- TrendDOWNTREND
10% below its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 22.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| UBS Group AG | DOUBLED | $215.7M |
| FMR LLC | TRIM | $191.3M |
| AMERIPRISE FINANCIAL INC | DOUBLED | $124.1M |
| JANE STREET GROUP, LLC | DOUBLED | $102.8M |
| PRICE T ROWE ASSOCIATES INC /MD/ | TRIM | $100.5M |
| ALLIANCEBERNSTEIN L.P. | ADD | $99.2M |
| TORONTO DOMINION BANK | ADD | $97.4M |
| Hood River Capital Management LLC | TRIM | $90.8M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
26 analystsPrice is below the lowest target. Median implies +56%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 4, 2026 | Canaccord Genuity MAINTAIN | Buy |
| Nov 4, 2026 | Truist Securities REITERATE | Buy |
| Nov 3, 2026 | Citigroup MAINTAIN | Buy |
| Sep 23, 2026 | Citigroup INITIATE | Buy |
| Aug 4, 2026 | Wolfe Research UPGRADE | Outperform |
| Aug 3, 2026 | Barclays MAINTAIN | Overweight |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Kelley Shannon T General Counsel Nov 6, 2026 | SELL | $430.8K |
BAKER BROS. ADVISORS LP Director Nov 6, 2026 | BUY | $793.2K |
BAKER BROS. ADVISORS LP Director Nov 6, 2026 | BUY | $23.1M |
BAKER BROS. ADVISORS LP Director Nov 6, 2026 | BUY | $5.3M |
BAKER BROS. ADVISORS LP Director Nov 4, 2026 | BUY | $3.7M |
BAKER BROS. ADVISORS LP Director Nov 4, 2026 | BUY | $2.1M |
Sibold William John President and CEO Sep 11, 2026 | SELL | $32.0K |
Sibold William John President and CEO Sep 11, 2026 | SELL | $116.8K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | -$2.00 | -$2.00–-$2.00 | +69.2% | $1.6B |
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
16 filings · 2 press releases · 6 bullish · 0 bearish · 1 mixed · 9 neutral- NEUTRAL SC 13G/ANov 16, 2026
RTW Investments, LP filed an amended Schedule 13G disclosing a passive 1.4% stake (312,817 shares) in Madrigal Pharmaceuticals as of September 30, 2026. The stake is unchanged from the prior filing, indicating no material change in the fund's position.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13D/ANov 6, 2026
Analysis based on filing metadata only; document content was unavailable. This is an amendment to…
Monitor for the actual SC 13D/A filing content to determine whether the activist investor increased or decreased their stake and whether their purpose or demands changed. The recent Q3 earnings…
- BULLISH INSIDER-BUYNov 6, 2026
Baker Bros. Advisors, a director and top institutional holder, made a $2.05M open-market purchase…
The Baker Bros. purchase cluster signals strong insider alignment with the company's post-earnings trajectory. Monitor next quarter's Rezdiffra sales trajectory and the MAESTRO-CSPH trial enrollment…
- BULLISH CLUSTERNov 6, 2026
Baker Bros. Advisors, a director and top holder, made open-market purchases totaling $35.0M over…
The cluster of large open-market purchases by the largest institutional holder immediately after a strong earnings beat signals conviction in the company's growth trajectory. Monitor for any insider…
All MDGL filing & press-release reports (18)
- SC 13G/A reportNov 16, 2026
- SC 13D/A reportNov 6, 2026
- INSIDER-BUY reportNov 6, 2026
- CLUSTER reportNov 6, 2026
- 144 reportNov 6, 2026
- INST-CLUSTER reportNov 5, 2026
- PRESS-RELEASE reportNov 5, 2026
- 8-K reportNov 3, 2026
- PRESS-RELEASE reportNov 3, 2026
- 8-K reportAug 12, 2026
- 8-K reportJul 30, 2026
- CLUSTER reportMay 22, 2026
- 8-K reportMay 6, 2026
- 8-K reportApr 28, 2026
- PRESS-RELEASE reportApr 22, 2026
- PRESS-RELEASE reportMar 19, 2026
- CLUSTER reportMar 2, 2026
- CLUSTER reportMar 2, 2026